CLDN4 and ovarian carcinoma: A recent study by a Japanese group [130] reported that ovarian cancer tissues from platinum-resistant patients have higher levels of claudin-4 expression than those from chemosensitive patients, and suppression of claudin-4 increased the sensitivity of ovarian cancer cells to cisplatin.